Literature DB >> 9693003

Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide.

H Shimizu1, R A Field, S W Homans, A Donohue-Rolfe.   

Abstract

We report the solution structure of the carbohydrate-binding B subunit of verotoxin VT-1 (VTB) from enterohemorrhagic Escherichia coli in association with the trisaccharide Galalpha1-4Galbeta1-4Glcbeta1-O-trimethylsilylethyl , determined by use of stable isotope-assisted NMR techniques. In contrast to the crystal structure of the complex which predicts three binding sites per monomer, only one of these sites is observed with substantial occupancy by the trisaccharide in solution.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9693003     DOI: 10.1021/bi980946+

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

1.  Development of recombinant B subunit of Shiga-like toxin 1 as a probe to detect carbohydrate ligands in immunochemical and flowcytometric application.

Authors:  S Miyashita; Y Matsuura; D Miyamoto; Y Suzuki; Y Imai
Journal:  Glycoconj J       Date:  1999-11       Impact factor: 2.916

2.  Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.

Authors:  Abhineet S Sheoran; Igor P Dmitriev; Elena A Kashentseva; Ocean Cohen; Jean Mukherjee; Michelle Debatis; Jonathan Shearer; Jacqueline M Tremblay; Gillian Beamer; David T Curiel; Charles B Shoemaker; Saul Tzipori
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

3.  The 13C4 monoclonal antibody that neutralizes Shiga toxin Type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide.

Authors:  Michael J Smith; Humberto M Carvalho; Angela R Melton-Celsa; Alison D O'Brien
Journal:  Infect Immun       Date:  2006-10-09       Impact factor: 3.441

Review 4.  Shiga toxins--from cell biology to biomedical applications.

Authors:  Ludger Johannes; Winfried Römer
Journal:  Nat Rev Microbiol       Date:  2009-12-21       Impact factor: 60.633

5.  Monoclonal antibody to Shiga toxin 2 which blocks receptor binding and neutralizes cytotoxicity.

Authors:  H Nakao; N Kiyokawa; J Fujimoto; S Yamasaki; T Takeda
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 6.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Interaction of the verotoxin 1B subunit with soluble aminodeoxy analogues of globotriaosyl ceramides.

Authors:  Murugesapillai Mylvaganam; Henrik C Hansen; Beth Binnington; Göran Magnusson; Per-Georg Nyholm; Clifford A Lingwood
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

8.  Production and characterization of protective human antibodies against Shiga toxin 1.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2.

Authors:  Kwang-il Jeong; Susan Chapman-Bonofiglio; Pradeep Singh; Jongo Lee; Saul Tzipori; Abhineet S Sheoran
Journal:  BMC Immunol       Date:  2010-03-24       Impact factor: 3.615

10.  Comparison of binding platforms yields insights into receptor binding differences between shiga toxins 1 and 2.

Authors:  Michael J Flagler; Sujit S Mahajan; Ashish A Kulkarni; Suri S Iyer; Alison A Weiss
Journal:  Biochemistry       Date:  2010-03-02       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.